Astel­las wins ap­proval in Japan for Claudin18.2 ther­a­py af­ter US re­jec­tion

Astel­las won ap­proval in Japan for Vy­loy, its gas­tric can­cer drug that was re­ject­ed by the FDA in Jan­u­ary over man­u­fac­tur­ing is­sues.

Vy­loy, al­so known as zol­be­tux­imab, tar­gets a pro­tein called Claudin18.2 (CLDN18.2) that’s ex­pressed on the sur­face of gas­tric can­cer cells. Oth­er drug­mak­ers are test­ing sim­i­lar ap­proach­es, in­clud­ing Leap Ther­a­peu­tics and As­traZeneca. But Astel­las said Tues­day that Vy­loy is the first of its class to re­ceive ap­proval world­wide.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER